Across TCGA pan-cancer cohorts, LINC00471 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LINC00471 data layer compared with 26 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LINC00471 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC00471 expression acts as an unfavorable survival marker.
LIHC, PRAD, and BLCA are the cancer types where LINC00471 Mutation most reproducibly stratifies survival.